Aeterna Zentaris (TSE:AEZS) Stock Price Down 38.5% – Time to Sell?

Aeterna Zentaris Inc. (TSE:AEZS) dropped 38.5% during mid-day trading on Monday . The stock traded as low as C$5.10 and last traded at C$5.10. Approximately 286 shares traded hands during trading, a decline of 75% from the average daily volume of 1,137 shares. The stock had previously closed at C$8.29.

Aeterna Zentaris Price Performance

The company has a current ratio of 5.94, a quick ratio of 9.37 and a debt-to-equity ratio of 1.80. The stock has a market capitalization of C$15.61 million, a PE ratio of -1.60 and a beta of 2.26. The firm’s 50-day moving average price is C$5.65 and its 200-day moving average price is C$7.38.

Aeterna Zentaris Company Profile

Aeterna Zentaris Inc, a specialty biopharmaceutical company, engages in developing and commercializing therapeutics and diagnostic tests in Canada, Switzerland, Ireland, Denmark, Germany, the United States, and internationally. Its lead product is Macrilen (macimorelin), an orally available peptidomimetic ghrelin receptor (GHSR-1a) agonist that stimulates the secretion of growth hormone by binding to the GHSR-1a for the diagnosis of patients with adult growth hormone deficiency and childhood-onset growth hormone deficiency, as well as endocrinology and oncology indications; AEZS-150, a delayed clearance parathyroid hormone fusion polypeptide that is in preclinical trial for the treatment of chronic hypoparathyroidism; and AEZS-130 that is in preclinical trial for the treatment of amyotrophic lateral sclerosis.